We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Matthew Mossanen MD, MPH

Matthew Mossanen MD, MPH

Assistant Professor of Surgery, Harvard Medical School, Brigham and Women's Hospital, Division of Urology, Boston, Massachusetts

Recent Contributions to PracticeUpdate:

  1. ASCO 2022: Abstract Recommendations From Dr. Matthew Mossanen for Bladder Cancer
  2. 2021 Top Story in Bladder Cancer: Pembrolizumab Monotherapy for BCG-Unresponsive Carcinoma
  3. EAU Guidelines on Non–Muscle-Invasive Bladder Cancer
  4. ESMO 2021: Recommendations From Dr. Matthew Mossanen for Urothelial Carcinoma
  5. The Impact of Smoking on Outcomes After Radical Cystectomy for Bladder Cancer
  6. Impact of Neoadjuvant Chemotherapy on Bladder Cancer Outcomes
  7. An Overview of Risk Factors for Bladder Cancer
  8. Gemcitabine, Cisplatin, and Nivolumab With Selective Bladder Sparing in Muscle-Invasive Cancer
  9. Pembrolizumab Monotherapy for the Treatment of High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to BCG
  10. 2020 Top Stories in Bladder Cancer: Nadofaragene Firadenovec Emerges as a New Treatment Option for BCG-Unresponsive Disease

Most Read This Week

Recently Updated